Skip to content

Etiology, diagnostics and management of bruxism

Etiology, diagnostics and management of bruxism - Bruxism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38435
Enrollment
174
Registered
2014-01-16
Start date
2013-12-04
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bruxism tooth-clenching tooth-grinding

Interventions

(A, B) No intervention. (C) Control group receives standard care (counseling and sleep hygiene), and intervention group receives standard care and stretching exercises.

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (A) Study on etiology - Age: adults of >18 years - Is aware of his/her clenching and/or grinding and/or his/her bed partner notice this;(B) Study on diagnostics - Age: 20-45 years - Awareness of presence or absence of clenching and/or grinding;(C) Study on management - Age: 20-45 years - Clear signs (partner/intraoral) and/or the subject is aware of his/her clenching and/or grinding

Exclusion criteria

Exclusion criteria: (A) Study on etiology - Presence of neurological disorders, neoplasms, psychiatric diseases - Removable intraoral device, such as a full prothesis, frame prothesis or plate prothesis - Treatment for TMD or bruxism - Orthodontic treatment at the moment - Use of medication which can influence the clenching and grinding - Use of soft/harddrugs - Toothache - Dental treatment in the next 6 months, with plans for crowns, bridges, prothesis of more than one filling;(B) Study on diagnostics, and (C) Study on management - Waking up with a pain complaint in the orofacial region - Absence of natural teeth in the front, the presence of loose and/or painful elements - Dislocated temporomandibular joint - Limited mouth opening - Excessive use of alcohol - Use of soft/harddrugs - Use of medication affecting sleep or motor behavior (psychotropic drugs, such as amphetamines, benzodiazepines, L-dopa, antipsychotics, tricyclic antidepressants, SSRI) - Neurological and neuromuscular disorders with effects on motor skills (such as epilepsy, Parkinson's disease, SMA, Duchenne muscular dystrophy) - Psychiatric disorders (such as schizophrenia) - Severe systemic diseases (such as MS).

Design outcomes

Primary

MeasureTime frame
(A) Self-reported awake and sleepbruxism, anger and frustration. (B, C) Established criteria for sleepbruxism (bruxism episodes per hour, bruxism bursts per episode/hour, episodes with sounds).

Secondary

MeasureTime frame
(A) Use of alcohol, smoking, anxiety, stress, sleep quality. (B) Subjective experiences with TeleBrux, sleep quality. (C) Experiences with sleep quality, bruxism and stretching, range of motion of the jaw, pain threshold and pain tolerance, pain, bite force, mandibular function.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)